Commenting on the publication of the interim report of the Accelerated Access Review, Alison Clough, Acting CEO of the Association of the British Pharmaceutical Industry (ABPI), said:
“We know that the UK lags behind many countries in providing our patients with access to new medicines and we are pleased that this interim report takes on board a number of ABPI recommendations to address this.
"Recognition of the need to ‘invest to save’ is a significant step forward. New medicines should be seen as a long-term investment and not simply as a cost; if we invest wisely in the right treatments for patients they will benefit from improved outcomes often resulting in NHS savings over the longer term.
Improved access to new medicines will not only be beneficial to patients but will also provide a boost to the life-sciences industry and the UK economy. The attractiveness of the UK as a place to do business and invest in innovative new treatments and technologies, ultimately depends on whether companies can research, launch and sell medicines in the UK, and we are pleased this has been recognised by the review.
The report discusses the need to balance patient access to new products while ensuring healthcare budgets are sustainable. The current Pharmaceutical Price Regulation Scheme (PPRS) was set up for exactly this reason. The pharmaceutical industry continues to provide financial support to the NHS to provide new medicines to patients by underwriting growth in the branded medicines bill to within agreed limits, yet more patients could and should be benefitting. This five year scheme provides a unique opportunity to ensure that this report is turned into operational reality for the benefit of patients, the NHS and the UK as a whole.
We look forward to working with the review team, NHS and other stakeholders, to consider how they can practically deliver these exciting proposals and make the changes required.”
To see the full ABPI submission to the Accelerated Access Review, click here.
About the ABPI
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Media Team Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 7147Email: firstname.lastname@example.org.